Home›Trial›NCT05064553
NCT05064553ACTIVE NOT RECRUITING

ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk

Study Summary

The primary objective is to assess overall sensitivity and specificity of Oncoguard™ Liver for hepatocellular cancer (HCC) detection in a surveillance population.

Conditions
Hepatocellular CarcinomaHepatocellular CancerHepatitis BCirrhosisLiver Cancer
Interventions / Drugs
Study CT/MRI ImagingStandard of Care CT/MRI ImagingOncoguard™ Liver Test
View on ClinicalTrials.gov ↗
Sponsor
EXAS
Exact Sciences
Diagnostics
D43/100
Study Details
Enrollment2990 participants
Primary Completion—
Lead SponsorExact Sciences Corporation
Data Retrieved2026-04-11 04:13:38.204300+00:00
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

Enrollment is complete. The trial is in its follow-up or data collection phase — a readout may occur on or near the primary completion date.

Enrolled: 2,990 participants
Sponsor Catalyst Profile

Exact Sciences (EXAS) is the sponsoring company for this trial. BiotechSign currently grades this company D (43/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

EXAS Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.